Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S)

The Lancet

Volumn 345, Issue 8960, 1995, Pages 1274-1275

  Scandinavian Simvastation Survival Study Group, ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029004377     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(95)90926-5     Document Type: Article

References (10)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
2. Secondary prevention of coronary disease with lipid-lowering drugs
3. Natural history of myocardial infarction in the Coronary Drug Project long-term prognostic importance of serum lipid levels
4. Prognostic importance of cholesterol levels after myocardial infarction
5. Serum lipids and lipoproteins after myocardial infarction: associations with cardiovascular mortality and experience in the Aspirin Myocardial Infarction Study
6. An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence
7. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease
8. Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction
9. An updated coronary risk profile: a statement for health professionals
10. The oxidation hypothesis of atherosclerosis